Vitreoretinal explant
Commonly used acronym: VR explant
Scope of the method
- Human health
- Basic Research
- In vitro - Ex vivo
- Animal derived cells / tissues / organs
Description
- intravitreal injection
- ocular delivery
- retinal delivery
- nanomedicines
- vitreal mobility
- inner limiting membrane
- ocular delivery
- nanomedicines
- intravitreal stability
- retinal delivery
- bovine eyes
Retinal gene delivery via intravitreal injection is hampered by various physiological barriers present in the eye of which the vitreoretinal (VR) interface represents the most serious hurdle. We present a retinal explant model especially designed to study the role of this interface as a barrier for the penetration of vectors into the retina. In contrast to all existing explant models, the developed model is bovine-derived and more importantly, keeps the vitreous attached to the retina at all times to guarantee an intact VR interface. After ex vivo intravitreal injection into the living retinal explant, the route of fluorescent carriers across the VR interface (vitreous and inner limiting membrane) can be tracked.
- Published in peer reviewed journal
Pros, cons & Future potential
Representative vitreous and inner limiting membrane intravitreal injections possible.
- Only viable for 1-2 days ;
- No vitreal flow or clearance pathways present.
Could be adapted to whole eye model with perfusion to mimick vitreal flows.
References, associated documents and other information
Karen Peynshaert, Joke Devoldere, Valérie Forster, Serge Picaud, Christian Vanhove, Stefaan C. De Smedt & Katrien Remaut (2017) Toward smart design of retinal drug carriers: a novel bovine retinal explant model to study the barrier role of the vitreoretinal interface, Drug Delivery, 24:1, 1384-1394, DOI: 10.1080/10717544.2017.1375578
Contact person
Katrien RemautOrganisations
Ghent University (UGent)Faculty of Pharmaceutical Sciences
Belgium
Flemish Region